Almanac Health Raises $10M Seed to Build AI Clinical Decision Support for Physicians

A physician sits in front of a screen, caught between instinct and information, scrolling through noise that doesn’t have time to be wrong. The clock isn’t loud, but it’s always ticking. Every decision carries weight, and most tools weren’t built for that kind of pressure. Almanac Health stepped into that gap, not to add more data, but to make what matters show up when it counts.

Boston just gave us a fresh signal. Almanac Health locked in $10M in seed funding, led by F-Prime, with General Catalyst, Lightspeed Venture Partners, and Soma Capital all leaning in like they’ve seen this movie before and know how it ends. Total funding now sitting just shy of $12M. Not loud money. Smart money.

Now track the origin story because that’s where this starts to separate. Cyril Zakka, MD, Founder and CEO, didn’t reverse-engineer a trend. This came out of Stanford, where retrieval-augmented generation in medicine moved from academic curiosity to something clinicians could actually lean on. One of the most cited papers in NEJM AI is less a credential and more a breadcrumb trail to what Almanac Health is building now. Add in time leading health AI at Hugging Face, and you start to see the pattern.

Almanac Health isn’t trying to out-chat the chatbot crowd. It’s building a research-validated clinical AI platform that actually respects the weight of a medical decision. Specialist-grade insight, delivered at the point of care, grounded in evidence, not influenced by pharma dollars, and governed like it belongs in a hospital, not a growth hack deck.

The tension here is simple. Clinicians don’t need more information. They need the right information, fast, defensible, and rooted in reality. Almanac Health is betting that trust becomes the real interface layer in clinical AI, and in healthcare, that’s not a feature, it’s the whole product.

The play here is discipline. Start with peer-reviewed foundations. Build with institutional guardrails. Integrate into EHR workflows where decisions actually happen. No shortcuts, no sugar rush. Just infrastructure that earns its place.

Capital is starting to move accordingly. In a market full of AI that performs well in controlled demos, this is money flowing toward something shaped by real-world constraints, where accuracy isn’t a metric, it’s a requirement.

Almanac Health is reading from a different kind of book. Not bedtime stories for investors, but something closer to a field manual for the future of clinical decision-making. And if they get it right, the quietest product in the room might end up being the one every physician listens to.